475a.T

475A.T maintains a strong liquidity position with a current ratio of 1.6 and a price-to-book ratio of 5.1, indicating a solid balance sheet and market valuation relative to its tangible assets. The company's cash and equivalents amount to ¥444.85 million, which supports its operational flexibility and financial stability.

The company's profitability is reflected in a return on equity of 26.99% and a return on assets of 11.79%, both of which are strong indicators of efficient capital use and asset management. These metrics suggest that 475A.T is performing well in terms of generating returns for its shareholders and utilizing its assets effectively.

475A.T's revenue is concentrated in the health care technology segment, with no disclosed geographic diversification in the provided data. This concentration may expose the company to specific market risks, particularly in the health care sector.

The company's growth trajectory is supported by a positive free cash flow of ¥257.25 million and a capital expenditure of -¥22.61 million, indicating that it is generating sufficient cash to fund its operations and potentially invest in future growth. The operating cash flow of ¥212.07 million further reinforces its ability to sustain and expand its business.

475A.T is currently assessed as having low liquidity and dilution risks, with no immediate filing-based liquidity or dilution flags detected. The company's debt-to-equity ratio of 0.32 suggests a conservative capital structure, reducing the likelihood of financial distress. The absence of dilution potential and the alignment of basic and diluted shares outstanding indicate that the company is not currently issuing additional shares to raise capital.

Recent events and filings have not indicated any significant changes in the company's financial or operational status. The company's financial snapshot and valuation metrics remain stable, with no notable deviations from its historical performance.